TL;DR: Oura is buying Counsel Health, the AI-and-doctor telehealth startup it’s been quietly running inside its own app since June, for $625 million. Counsel’s CEO becomes Oura’s chief clinical AI officer, its 70 employees join the ring maker, and the deal is expected to close before the end of 2027. It’s Oura’s fourth health-data acquisition this year, and it lands just weeks after the company shelved an IPO that could have valued it at up to $2.2 billion.
Oura announced the acquisition Tuesday, putting a hard number on a relationship that’s been building for months. Counsel Health pairs a chat-based medical AI with a network of licensed physicians, and Oura has had that pairing live inside its own app since June, letting ring wearers who flag an odd symptom or a worrying trend in their data go straight into a conversation with the AI and, when needed, a real doctor. Buying the company outright turns that integration from a partnership into something Oura owns end to end.
The price tag matters here. $625 million is a huge multiple for a startup that, according to PitchBook, has raised something like $36 million total, including a $25 million Series A a year ago led by a16z and GV. Counsel’s 70 employees are moving over as part of the deal, and founder and CEO Muthu Alagappan is taking the title of chief clinical AI officer at Oura, according to Bloomberg. That’s not a vague “advisor” role. It’s a seat at the table for how Oura builds actual medical judgment into a product that, until recently, mostly told people how well they slept.
That shift says a lot about where Oura thinks the money is. The company posted $533 million in third-quarter revenue, up 153% year over year, and is on pace for roughly $1.75 billion for fiscal 2026. Numbers like that don’t come from ring sales alone anymore. They come from subscriptions, from data, and increasingly from the promise that a $300 piece of jewelry can tell you something a checkup might miss. Owning the clinical layer, rather than renting it from a partner, is how Oura protects that story and keeps the margin.
Counsel Health isn’t Oura’s first health-data purchase of the year, and it probably won’t be the last. In March, Oura bought Doublepoint, a gesture-recognition company, in a move tied to its own long-rumored IPO ambitions. In April it picked up Galen, described at the time as an AI health companion aimed at accelerating Oura’s connected health AI roadmap. Not long after that, it acquired Veri, a metabolic health company that tracks blood sugar and diet response. Counsel Health is the fourth deal in that run, and it’s the one that pushes furthest past wearable data and into something that looks a lot more like a medical provider.
That’s worth sitting with. A smart ring company buying a telehealth startup with its own network of licensed doctors is a different kind of move than buying a gesture-sensor company or a blood-sugar app. Counsel isn’t just software. It’s a clinical operation, with real physicians, real patient interactions, and the regulatory exposure that comes with both. Folding that into a consumer hardware company is a bet that Oura wants to be judged less like Fitbit and more like a health system with a really good front door.
The timing adds another layer. Oura had been pursuing an IPO that reports pegged at up to a $2.2 billion valuation, and the company indefinitely postponed those plans before this deal was announced. Spending $625 million on an acquisition right after shelving a public offering isn’t necessarily a sign of trouble. Plenty of companies choose to build out their product before facing public markets, and Oura’s revenue growth gives it room to make that case. But it does suggest Oura would rather show up to Wall Street as a health platform with its own doctors than as a wearable maker asking investors to take the clinical ambition on faith.
It also puts pressure on the rest of the wearable field. Apple, Samsung, and a stack of smaller ring and band makers have all leaned into health framing over the past couple of years, folding AI models and benchmark comparisons into their marketing the same way Anthropic and OpenAI trade valuation numbers in their own funding rounds. Most of that has stayed at the level of insight and nudges, sleep scores, readiness scores, a notification suggesting you take it easy today. Counsel Health is a step past that, actual physicians attached to actual AI triage, inside the ring’s own app. If it works, and if Oura can keep the regulatory and liability side clean, competitors are going to feel pressure to either build or buy something similar rather than ship another dashboard update.
Wall Street and health-tech investors have been pushing exactly this kind of consolidation for a while now. The pitch for years was that wearables collect enormous amounts of biometric data with nowhere useful for it to go, no clinician reading it, no care pathway attached to the numbers on the screen. Counsel Health existing as a standalone AI-plus-doctor service answered that gap from outside Oura’s walls, which is exactly why folding it in-house, rather than renewing a partnership agreement year after year, reads as more than a routine tuck-in acquisition.
There are real open questions. Buying a 70-person telehealth operation with licensed doctors across however many states means Oura inherits malpractice exposure, state-by-state telehealth licensing rules, and the kind of compliance overhead that hardware companies don’t usually carry. Alagappan’s new title suggests Oura knows that and wants clinical leadership embedded at the top rather than treated as a bolt-on. Whether that holds up once the integration moves past the current app partnership and into a full in-house build is the part nobody outside the company can answer yet.
The bottom line
Oura didn’t need to buy a doctor’s office to sell rings, but it chose to anyway, and that choice is the real story here. A wearable company willing to pay $625 million and hand a clinical title to an outside CEO is telling you it no longer wants to be in the business of data alone. It wants to own the diagnosis. That’s a bigger, riskier, and honestly more interesting bet than another acquisition for a sensor or an algorithm, and it’s going to be worth watching whether the rest of the wearable industry follows Oura into actual medicine, or waits to see if the liability catches up with it first.
The Teck Hustlers Editorial Team covers technology, business, finance and gaming news for readers who want the story behind the headline. Every article is researched, written and edited by our in-house team, checked against company announcements, filings and reputable reporting, and updated when new facts emerge. We focus on what each development means for founders, professionals, investors and everyday users. Have a tip or a correction? Reach us through our contact page.
